Liver transduction with an AAV vector expressing a gain-of-function mutation of PCSK9 under the control of the human α1-antitrypsin promoter induces stable changes in plasma lipid profile and atherosclerosis [9, 10]. This evidence concerns the gene PCSK9 and atherosclerosis.